eligibility_summary
Inclusion: adults (≥18) with PMBCL, EBV+ DLBCL, or THRLBCL, archival/new tumor tissue, CAR‑T candidates (≥2 prior lines or refractory/early relapse or not HSCT‑fit), ECOG 0–1, LVEF ≥50%, adequate labs/organ function, measurable FDG‑avid lesion. Exclusion: urgent cytoreduction, recent vaccines/anticancer therapy, prior CAR‑T, PD‑1/PD‑L1 failure or severe irAEs, active CNS disease or infection, HBV/HCV/HIV, serious cardiac/CNS/autoimmune/ILD/liver disease, high‑dose steroids, pregnancy/lactation, pembrolizumab allergy, prior solid organ/allo‑SCT or recent auto‑SCT, prior MAS/HLH.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in relapsed/refractory PMBCL (plus small cohorts of EBV+ DLBCL and THRLBCL) testing pembrolizumab with standard CD19-directed CAR T cells (axicabtagene ciloleucel or lisocabtagene maraleucel) after lymphodepleting chemotherapy. Interventions and mechanisms: Pembrolizumab—humanized monoclonal antibody immune checkpoint inhibitor that blocks PD-1 on T cells, restoring anti-tumor activity by inhibiting PD-1/PD-L1 signaling, CAR T therapies—autologous, genetically engineered T cells expressing a CD19-specific chimeric antigen receptor that recognizes and kills malignant B cells, Lymphodepletion—fludarabine (purine analog) and cyclophosphamide (alkylating agent) to deplete host lymphocytes and support CAR T expansion. Targets/pathways: PD-1/PD-L1 axis on T cells/tumor microenvironment and CD19 on B-cell lymphomas.